Want to see PMN full AI Analyst Report?
PMN Stock Chart & Stats
$8.12
-$0.04(-3.74%)
At close: 4:00 PM EST
$8.12
-$0.04(-3.74%)
Day’s Range― - ―
52-Week Range$6.27 - $39.75
Previous CloseN/A
Volume32.49K
Average Volume (3M)819.50K
Market Cap
$28.33M
Enterprise Value-$50.24M
Total Cash (Recent Filing)$63.85M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Aug 17, 2026EPS Estimate
-1.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-23.59
Shares Outstanding2,152,397
10 Day Avg. Volume1,049,009
30 Day Avg. Volume819,497
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-9.53K
Price to Sales (P/S)0.00
P/FCF Ratio-426.74
Enterprise Value/Market Cap-1.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.22
Forecast
1Y Price Target
$33.55Price Target Upside313.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-5.43
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance SheetThe company’s lack of debt and a sizeable equity base materially reduce solvency risk and preserve flexibility to fund multi-year clinical programs. Low leverage supports the ability to pursue R&D, partner deals, or bridge financing without immediate pressure from interest burdens.
Focused R&D PlatformProMIS’s platform targeting toxic protein species in neurodegeneration reflects a durable, mechanism-driven strategy. A focused antibody approach aligns with structural demand from aging populations and allows concentrated scientific investment that, if successful, can create differentiated, high-value assets.
Governance And Incentive AlignmentRecent shareholder approval of directors, auditor ratification, and an expanded equity incentive reserve indicate governance stability and stronger tools to retain scientific and management talent. Stable governance and retention capacity are important for executing long clinical timelines.
Bears Say
Pre-Revenue With Large LossesBeing pre-revenue and running multi‑tens-of-millions in annual losses creates persistent financing needs. Over the next several quarters this dynamic increases reliance on external capital, raises dilution risk, and can constrain the pace or scope of clinical development absent sizable partnerships or non-dilutive funding.
Consistent Negative Cash FlowSustained negative operating and free cash flow undermine the company’s ability to self-fund trials or scale operations. Persistent cash burn reduces strategic optionality, increases the probability of repeated financing rounds, and elevates execution risk for multi-year R&D programs.
Inconsistent Equity PositionHistorical episodes of negative equity signal volatile capital structure and past funding stress. Inconsistent equity undermines perceived financial stability, can limit access to certain non-dilutive financings or collaborations, and raises the bar for creditor or partner confidence during long development cycles.
ProMIS Neurosciences News
PMN FAQ
What was ProMIS Neurosciences’s price range in the past 12 months?
ProMIS Neurosciences lowest stock price was $6.27 and its highest was $39.75 in the past 12 months.
What is ProMIS Neurosciences’s market cap?
ProMIS Neurosciences’s market cap is $28.33M.
When is ProMIS Neurosciences’s upcoming earnings report date?
ProMIS Neurosciences’s upcoming earnings report date is Aug 17, 2026 which is in 47 days.
How were ProMIS Neurosciences’s earnings last quarter?
ProMIS Neurosciences released its earnings results on May 12, 2026. The company reported -$1.26 earnings per share for the quarter, missing the consensus estimate of -$1.06 by -$0.2.
Is ProMIS Neurosciences overvalued?
According to Wall Street analysts ProMIS Neurosciences’s price is currently Undervalued.
Does ProMIS Neurosciences pay dividends?
ProMIS Neurosciences does not currently pay dividends.
What is ProMIS Neurosciences’s EPS estimate?
ProMIS Neurosciences’s EPS estimate is -1.44.
How many shares outstanding does ProMIS Neurosciences have?
ProMIS Neurosciences has 2,152,397 shares outstanding.
What happened to ProMIS Neurosciences’s price movement after its last earnings report?
ProMIS Neurosciences reported an EPS of -$1.26 in its last earnings report, missing expectations of -$1.06. Following the earnings report the stock price went down -1.779%.
Which hedge fund is a major shareholder of ProMIS Neurosciences?
Currently, no hedge funds are holding shares in PMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
PMN Stock 12 Month Forecast
Average Price Target
$33.55
▲(313.18% Upside)